Updated:
Lanting Capital
LanTing Capital is a cross-border, pharmaceutical-focused strategic consulting and investment firm. It has made 14 investments, including a Series B investment...
Lanting Capital
LanTing Capital is a cross-border, pharmaceutical-focused strategic consulting and investment firm. It has made 14 investments, including a Series B investment in Regor Therapeutics on February 19, 2021. The firm has 2 portfolio exits, with Yunji Technology being its latest exit on October 16, 2025.
General information
Firm type
Venture Capital
Year founded
2017
Location
Region
Asia
Country
China
City
Hangzhou
Corporate office
Hangzhou, Zhejiang, China
Principals
Li Zhubin
Founding Partner
Sector focus
Frequently asked questions
Who runs investment decisions at Lanting Capital?
Founding partner Li Zhubin leads investment decisions. The firm operates with a lean partnership structure typical of early-stage venture managers in China, where the founding partner maintains direct oversight of deal sourcing and portfolio construction.
What investment stages does Lanting Capital target?
Lanting writes first-check seed and early-stage tickets. The firm positions itself as the first institutional capital into technically complex startups, typically entering before revenue scale and evaluating companies on engineering depth and IP defensibility rather than market traction.
Which sectors does Lanting Capital focus on?
The firm concentrates on deep-tech verticals — enterprise software, artificial intelligence and machine learning, and semiconductors. These align with China's industrial policy priorities and the Hangzhou-Shanghai corridor's technical talent base.
Does Lanting Capital co-invest alongside external partners?
Yes. The firm typically leads or co-leads seed rounds alongside other technically focused early-stage funds. Given its concentrated portfolio approach, Lanting seeks co-investors who bring complementary engineering networks rather than purely financial capital.
How does Lanting Capital source its deals?
Lanting relies on a technical founder-referral network and direct outreach to university and corporate R&D labs across China's core innovation hubs. The firm's diligence process mirrors an engineering review, assessing code repositories, semiconductor design tape-outs, and patent filings before committing capital.
Is Lanting Capital a corporate venture arm or independent firm?
Lanting is an independent, partner-led venture firm. No corporate parent or single-family wealth source has been publicly disclosed, and the firm operates without a strategic anchor LP that would constrain its investment mandate.
Where does Lanting Capital deploy geographically?
Primary deployment runs through China's four largest startup ecosystems — Hangzhou, Shanghai, Shenzhen, and Beijing. Hangzhou serves as the headquarters and anchor, reflecting the firm's proximity to Alibaba's talent ecosystem and Zhejiang University's engineering pipeline.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: